{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:35:26Z","timestamp":1787236526307,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T00:00:00Z","timestamp":1743984000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000138","name":"U.S. Department of Education","doi-asserted-by":"publisher","award":["P031C210118"],"award-info":[{"award-number":["P031C210118"]}],"id":[{"id":"10.13039\/100000138","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000138","name":"U.S. Department of Education","doi-asserted-by":"publisher","award":["P031C160152"],"award-info":[{"award-number":["P031C160152"]}],"id":[{"id":"10.13039\/100000138","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["P42 ES004699"],"award-info":[{"award-number":["P42 ES004699"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000066","name":"National Institute of Environmental Health Sciences","doi-asserted-by":"publisher","award":["R35 ES030443"],"award-info":[{"award-number":["R35 ES030443"]}],"id":[{"id":"10.13039\/100000066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U54 NS127758"],"award-info":[{"award-number":["U54 NS127758"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R16 GM150781"],"award-info":[{"award-number":["R16 GM150781"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"NIH National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["R16GM149204"],"award-info":[{"award-number":["R16GM149204"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["75N95023C00021"],"award-info":[{"award-number":["75N95023C00021"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["CHE1726903"],"award-info":[{"award-number":["CHE1726903"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemistry and Biophysics Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.bbrep.2025.102009","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T11:04:05Z","timestamp":1744283045000},"page":"102009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Synthesis and evaluation of isoquinolinyl and pyridinyl-based dual inhibitors of fatty acid amide hydrolase and soluble epoxide hydrolase to alleviate orofacial hyperalgesia in the rat"],"prefix":"10.1016","volume":"42","author":[{"given":"Daniel","family":"Carr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siena","family":"Gunari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Gorostiza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Mercado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Pavana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0064-5805","authenticated-orcid":false,"given":"Steve","family":"Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coral","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5672-6631","authenticated-orcid":false,"given":"Christophe","family":"Morisseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce D.","family":"Hammock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stevan","family":"Pecic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3254-2341","authenticated-orcid":false,"given":"Ram","family":"Kandasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bbrep.2025.102009_bib1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/ana.410160202","article-title":"The neurobiology of vascular head pain","volume":"16","author":"Moskowitz","year":"1984","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102009_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3988\/jcn.2012.8.2.89","article-title":"Sensitization of the trigeminovascular pathway: perspective and implications to migraine pathophysiology","volume":"8","author":"Bernstein","year":"2012","journal-title":"J. Clin. Neurol."},{"issue":"20","key":"10.1016\/j.bbrep.2025.102009_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252011306","article-title":"The trigeminal sensory system and orofacial pain","volume":"25","author":"Kim","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl 4","key":"10.1016\/j.bbrep.2025.102009_bib4","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/head.12601","article-title":"Triptans in the acute treatment of migraine: a systematic review and network meta-analysis","volume":"55","author":"Cameron","year":"2015","journal-title":"Headache"},{"issue":"3","key":"10.1016\/j.bbrep.2025.102009_bib5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/ana.21897","article-title":"Triptan-induced latent sensitization: a possible basis for medication overuse headache","volume":"67","author":"De Felice","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.bbrep.2025.102009_bib6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1186\/s40064-016-2211-8","article-title":"Recent advances in migraine therapy","volume":"5","author":"Antonaci","year":"2016","journal-title":"SpringerPlus"},{"key":"10.1016\/j.bbrep.2025.102009_bib7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.pharmthera.2017.06.006","article-title":"Soluble epoxide hydrolase as a therapeutic target for pain, inflammatory and neurodegenerative diseases","volume":"180","author":"Wagner","year":"2017","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102009_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-008-9075-y","article-title":"Targeting fatty acid amide hydrolase (FAAH) to treat pain and inflammation","volume":"11","author":"Schlosburg","year":"2009","journal-title":"AAPS J."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102009_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.plipres.2004.10.001","article-title":"Epoxide hydrolases: their roles and interactions with lipid metabolism","volume":"44","author":"Newman","year":"2005","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.bbrep.2025.102009_bib10","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1146\/annurev-pharmtox-011112-140244","article-title":"Impact of soluble epoxide hydrolase and epoxyeicosanoids on human health","volume":"53","author":"Morisseau","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bbrep.2025.102009_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146573","article-title":"Soluble epoxide hydrolase inhibitor mediated analgesia lacks tolerance in rat models","volume":"1728","author":"Wagner","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.bbrep.2025.102009_bib12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev.biochem.74.082803.133450","article-title":"Structure and function of fatty acid amide hydrolase","volume":"74","author":"McKinney","year":"2005","journal-title":"Annu. Rev. Biochem."},{"issue":"7","key":"10.1016\/j.bbrep.2025.102009_bib13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1517\/17460440903018857","article-title":"Fatty acid amide hydrolase as a potential therapeutic target for the treatment of pain and CNS disorders","volume":"4","author":"Ahn","year":"2009","journal-title":"Expet Opin. Drug Discov."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102009_bib14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0304-3959(01)00454-7","article-title":"CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain","volume":"96","author":"Clayton","year":"2002","journal-title":"Pain"},{"key":"10.1016\/j.bbrep.2025.102009_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/bs.apha.2017.03.007","article-title":"CB(1) and CB(2) receptor pharmacology","volume":"80","author":"Howlett","year":"2017","journal-title":"Adv. Pharmacol."},{"issue":"8","key":"10.1016\/j.bbrep.2025.102009_bib16","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1111\/j.1476-5381.2011.01445.x","article-title":"The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice","volume":"165","author":"Booker","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"51","key":"10.1016\/j.bbrep.2025.102009_bib17","doi-asserted-by":"crossref","first-page":"13318","DOI":"10.1523\/JNEUROSCI.3326-06.2006","article-title":"Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain","volume":"26","author":"Jhaveri","year":"2006","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.bbrep.2025.102009_bib18","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.aat.2013.10.004","article-title":"Targeting the cannabinoid system for pain relief?","volume":"51","author":"Chiou","year":"2013","journal-title":"Acta Anaesthesiol. Taiwanica"},{"key":"10.1016\/j.bbrep.2025.102009_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106841","article-title":"Peripheral soluble epoxide hydrolase inhibition reduces hypernociception and inflammation in albumin-induced arthritis in temporomandibular joint of rats","volume":"87","author":"Teixeira","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"8","key":"10.1016\/j.bbrep.2025.102009_bib20","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.euroneuro.2015.04.001","article-title":"Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice","volume":"25","author":"Nozaki","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.bbrep.2025.102009_bib21","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1177\/0333102414566862","article-title":"Effects of peripheral FAAH blockade on NTG-induced hyperalgesia--evaluation of URB937 in an animal model of migraine","volume":"35","author":"Greco","year":"2015","journal-title":"Cephalalgia"},{"key":"10.1016\/j.bbrep.2025.102009_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2019.104624","article-title":"FAAH inhibition as a preventive treatment for migraine: a pre-clinical study","volume":"134","author":"Greco","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbrep.2025.102009_bib23","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.phrs.2015.04.001","article-title":"Peripheral FAAH and soluble epoxide hydrolase inhibitors are synergistically antinociceptive","volume":"97","author":"Sasso","year":"2015","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.bbrep.2025.102009_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32262","article-title":"Quinolinyl-based multitarget-directed ligands with soluble epoxide hydrolase and fatty acid amide hydrolase inhibitory activities: synthetic studies and pharmacological evaluations","volume":"10","author":"Angelia","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bbrep.2025.102009_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104165","article-title":"Development of multitarget inhibitors for the treatment of pain: design, synthesis, biological evaluation and molecular modeling studies","volume":"103","author":"Wilt","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bbrep.2025.102009_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116507","article-title":"Further exploration of the structure-activity relationship of dual soluble epoxide hydrolase\/fatty acid amide hydrolase inhibitors","volume":"51","author":"Wilt","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbrep.2025.102009_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118112","article-title":"Structure-activity relationship studies and pharmacological evaluation of 4-phenylthiazoles as dual soluble epoxide hydrolase\/fatty acid amide hydrolase inhibitors","volume":"121","author":"Yuan","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bbrep.2025.102009_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2022.106702","article-title":"Structure-activity relationship studies of benzothiazole-phenyl analogs as multi-target ligands to alleviate pain without affecting normal behavior","volume":"164","author":"Angelia","year":"2023","journal-title":"Prostag. Other Lipid Mediat."},{"key":"10.1016\/j.bbrep.2025.102009_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadva.2024.100119","article-title":"4-Phenyl-thiazole-based dual inhibitors of fatty acid amide hydrolase and soluble epoxide hydrolase do not alleviate orofacial inflammatory pain in female rats","volume":"6","author":"Carr","year":"2024","journal-title":"BBA Adv"},{"issue":"2","key":"10.1016\/j.bbrep.2025.102009_bib30","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1124\/jpet.106.106377","article-title":"Preclinical assessment of candidate analgesic drugs: recent advances and future challenges","volume":"319","author":"Negus","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"2&3","key":"10.1016\/j.bbrep.2025.102009_bib31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/FBP.0000000000000596","article-title":"'Reinventing the wheel' to advance the development of pain therapeutics","volume":"32","author":"Kandasamy","year":"2021","journal-title":"Behav. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102009_bib32","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12955-016-0542-3","article-title":"Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches","volume":"14","author":"Mannix","year":"2016","journal-title":"Health Qual Life Outcomes"},{"issue":"6","key":"10.1016\/j.bbrep.2025.102009_bib33","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1097\/j.pain.0000000000000853","article-title":"Evaluating the impact of trigeminal neuralgia","volume":"158","author":"Zakrzewska","year":"2017","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.bbrep.2025.102009_bib34","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ab.2006.10.041","article-title":"Development of highly sensitive fluorescent assays for fatty acid amide hydrolase","volume":"363","author":"Huang","year":"2007","journal-title":"Anal. Biochem."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102009_bib35","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ab.2005.03.041","article-title":"Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies","volume":"343","author":"Jones","year":"2005","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.bbrep.2025.102009_bib36","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.prostaglandins.2018.02.004","article-title":"Novel piperidine-derived amide sEH inhibitors as mediators of lipid metabolism with improved stability","volume":"136","author":"Pecic","year":"2018","journal-title":"Prostag. Other Lipid Mediat."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102009_bib37","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.bmcl.2012.11.084","article-title":"Synthesis and structure\u2013activity relationship of piperidine-derived non-urea soluble epoxide hydrolase inhibitors","volume":"23","author":"Pecic","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"8","key":"10.1016\/j.bbrep.2025.102009_bib38","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1097\/j.pain.0000000000001872","article-title":"Increasing gender differences in the prevalence and chronification of orofacial pain in the population","volume":"161","author":"Haggman-Henrikson","year":"2020","journal-title":"Pain"},{"key":"10.1016\/j.bbrep.2025.102009_bib39","doi-asserted-by":"crossref","first-page":"891","DOI":"10.12688\/f1000research.18338.1","article-title":"A refinement to the formalin test in mice","volume":"8","author":"Lopes","year":"2019","journal-title":"F1000Res"},{"issue":"3","key":"10.1016\/j.bbrep.2025.102009_bib40","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0304-3940(89)90125-0","article-title":"Application of the formalin test to the study of orofacial pain in the rat","volume":"103","author":"Clavelou","year":"1989","journal-title":"Neurosci. Lett."},{"issue":"2","key":"10.1016\/j.bbrep.2025.102009_bib41","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.neubiorev.2003.12.003","article-title":"The orofacial formalin test","volume":"28","author":"Raboisson","year":"2004","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.bbrep.2025.102009_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2022.113956","article-title":"Modelling migraine-related features in the nitroglycerin animal model: trigeminal hyperalgesia is associated with affective status and motor behavior","volume":"256","author":"Demartini","year":"2022","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.bbrep.2025.102009_bib43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jneumeth.2016.02.013","article-title":"Home cage wheel running is an objective and clinically relevant method to assess inflammatory pain in male and female rats","volume":"263","author":"Kandasamy","year":"2016","journal-title":"J. Neurosci. Methods"},{"issue":"11","key":"10.1016\/j.bbrep.2025.102009_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e32262","article-title":"Quinolinyl-based multitarget-directed ligands with soluble epoxide hydrolase and fatty acid amide hydrolase inhibitory activities: synthetic studies and pharmacological evaluations","volume":"10","author":"Angelia","year":"2024","journal-title":"Heliyon"},{"issue":"4","key":"10.1016\/j.bbrep.2025.102009_bib45","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.chembiol.2009.02.013","article-title":"Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain","volume":"16","author":"Ahn","year":"2009","journal-title":"Chem. Biol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102009_bib46","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1021\/jm801042a","article-title":"Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors","volume":"52","author":"Wang","year":"2009","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.bbrep.2025.102009_bib47","doi-asserted-by":"crossref","first-page":"14076","DOI":"10.1021\/acsomega.8b01625","article-title":"Design and potency of dual soluble epoxide hydrolase\/fatty acid amide hydrolase inhibitors","volume":"3","author":"Kodani","year":"2018","journal-title":"ACS Omega"},{"issue":"4","key":"10.1016\/j.bbrep.2025.102009_bib48","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1021\/acs.jmedchem.0c01886","article-title":"Movement to the clinic of soluble epoxide hydrolase inhibitor EC5026 as an analgesic for neuropathic pain and for use as a nonaddictive opioid alternative","volume":"64","author":"Hammock","year":"2021","journal-title":"J. Med. Chem."},{"issue":"16","key":"10.1016\/j.bbrep.2025.102009_bib49","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1021\/jm070270t","article-title":"Orally bioavailable potent soluble epoxide hydrolase inhibitors","volume":"50","author":"Hwang","year":"2007","journal-title":"J. Med. Chem."},{"issue":"7428","key":"10.1016\/j.bbrep.2025.102009_bib50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nature11691","article-title":"Automated design of ligands to polypharmacological profiles","volume":"492","author":"Besnard","year":"2012","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.bbrep.2025.102009_bib51","doi-asserted-by":"crossref","first-page":"88","DOI":"10.5214\/ans.0972.7531.12190210","article-title":"Serotonin and CGRP in migraine","volume":"19","author":"Aggarwal","year":"2012","journal-title":"Ann. Neurosci."},{"issue":"18","key":"10.1016\/j.bbrep.2025.102009_bib52","doi-asserted-by":"crossref","first-page":"7379","DOI":"10.1073\/pnas.1016167108","article-title":"Discovery and molecular basis of potent noncovalent inhibitors of fatty acid amide hydrolase (FAAH)","volume":"108","author":"Min","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102009_bib53","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/cbdd.13670","article-title":"Design, microwave-assisted synthesis, biological evaluation and molecular modeling studies of 4-phenylthiazoles as potent fatty acid amide hydrolase inhibitors","volume":"95","author":"Wilt","year":"2020","journal-title":"Chem. Biol. Drug Des."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102009_bib54","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jcc.540150503","article-title":"ICM\u2014a new method for protein modeling and design: applications to docking and structure prediction from the distorted native conformation","volume":"15","author":"Abagyan","year":"1994","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bbrep.2025.102009_bib55","article-title":"Nitroglycerin as a model of migraine: clinical and preclinical review","volume":"12","author":"Sureda-Gibert","year":"2022","journal-title":"Neurobiol Pain"},{"issue":"2\u20133","key":"10.1016\/j.bbrep.2025.102009_bib56","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0014-2999(03)01421-3","article-title":"Nitroglycerin induces hyperalgesia in rats--a time-course study","volume":"464","author":"Tassorelli","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bbrep.2025.102009_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105157","article-title":"Characterization of the peripheral FAAH inhibitor, URB937, in animal models of acute and chronic migraine","volume":"147","author":"Greco","year":"2021","journal-title":"Neurobiol. Dis."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102009_bib58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/brain\/awy313","article-title":"Nitroglycerine triggers triptan-responsive cranial allodynia and trigeminal neuronal hypersensitivity","volume":"142","author":"Akerman","year":"2019","journal-title":"Brain"},{"issue":"13","key":"10.1016\/j.bbrep.2025.102009_bib59","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1177\/0333102416678000","article-title":"Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: targets and anti-migraine mechanisms","volume":"37","author":"Greco","year":"2017","journal-title":"Cephalalgia"},{"key":"10.1016\/j.bbrep.2025.102009_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110320","article-title":"Soluble epoxide hydrolase inhibitor blockage microglial cell activation in subnucleus caudalis in a persistent model of arthritis","volume":"120","author":"Tarkany Basting","year":"2023","journal-title":"Int. Immunopharmacol."},{"issue":"3","key":"10.1016\/j.bbrep.2025.102009_bib61","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1007\/s10787-022-00965-5","article-title":"Soluble epoxide hydrolase inhibition avoid formalin-induced inflammatory hyperalgesia in the temporomandibular joint","volume":"30","author":"Abdalla","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"14","key":"10.1016\/j.bbrep.2025.102009_bib62","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1177\/0333102415574846","article-title":"Mechanisms of glyceryl trinitrate provoked mast cell degranulation","volume":"35","author":"Pedersen","year":"2015","journal-title":"Cephalalgia"},{"issue":"10","key":"10.1016\/j.bbrep.2025.102009_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/cells13100830","article-title":"Effects of the dual FAAH\/MAGL inhibitor AKU-005 on trigeminal hyperalgesia in male rats","volume":"13","author":"Greco","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.bbrep.2025.102009_bib64","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1744-8069-7-78","article-title":"Soluble epoxide hydrolase limits mechanical hyperalgesia during inflammation","volume":"7","author":"Brenneis","year":"2011","journal-title":"Mol. Pain"},{"key":"10.1016\/j.bbrep.2025.102009_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2024.106443","article-title":"Role of soluble epoxide hydrolase in pain and depression comorbidity","volume":"193","author":"Bu","year":"2024","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.bbrep.2025.102009_bib66","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ejphar.2017.10.054","article-title":"Anti-migraine effect of \u03949-tetrahydrocannabinol in the female rat","volume":"818","author":"Kandasamy","year":"2018","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.bbrep.2025.102009_bib67","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/FBP.0000000000000382","article-title":"Medication overuse headache following repeated morphine, but not \u03949-tetrahydrocannabinol administration in the female rat","volume":"29","author":"Kandasamy","year":"2018","journal-title":"Behav. Pharmacol."},{"issue":"1","key":"10.1016\/j.bbrep.2025.102009_bib68","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s10194-017-0721-6","article-title":"Depression of home cage wheel running: a reliable and clinically relevant method to assess migraine pain in rats","volume":"18","author":"Kandasamy","year":"2017","journal-title":"J. Headache Pain"}],"container-title":["Biochemistry and Biophysics Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580825000962?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405580825000962?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T21:45:43Z","timestamp":1778881543000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405580825000962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":68,"alternative-id":["S2405580825000962"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102009","relation":{},"ISSN":["2405-5808"],"issn-type":[{"value":"2405-5808","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and evaluation of isoquinolinyl and pyridinyl-based dual inhibitors of fatty acid amide hydrolase and soluble epoxide hydrolase to alleviate orofacial hyperalgesia in the rat","name":"articletitle","label":"Article Title"},{"value":"Biochemistry and Biophysics Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrep.2025.102009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102009"}}